Keros Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
KROS$9.33+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| NINE MONTHS ENDED SEPTEMBER 30, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income (loss) | $(38,265) | $110,475 |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation expense | 1,189 | 1,109 |
| Gain on disposal of fixed asset | — | (14) |
| Stock-based compensation expense | 15,779 | 21,391 |
| Non-cash lease expense | 1,954 | 1,788 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (16,433) | (750) |
| Prepaid expenses and other current assets | 16,282 | 3,877 |
| Other assets | (11) | 2,056 |
| Accounts payable | 2,186 | (2,304) |
| Right-of-use assets and operating lease liabilities | (1,773) | (1,432) |
| Deferred revenue | — | 155 |
| Current tax liability | 615 | 4,147 |
| Accrued expenses and other current liabilities | (2,083) | (5,701) |
| Net cash provided by (used in) operating activities | (20,560) | 134,797 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (287) | (1,417) |
| Net cash used in investing activities | (287) | (1,417) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock under the employee stock purchase plan | 73 | 138 |
| Repurchase of treasury stock | (1,545) | — |
| Payment of direct expenses associated with the treasury stock repurchase | (5,664) | — |
| Proceeds from exercise of stock options | 32 | 23 |
| Net cash provided by (used in) financing activities | (7,104) | 161 |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (27,951) | 133,541 |
| Cash, cash equivalents and restricted cash at beginning of period | 288,864 | 561,380 |
| Cash, cash equivalents and restricted cash at end of period | $260,913 | $694,921 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||
| Cash paid for taxes | $— | $2,250 |
| Property and equipment purchases in accounts payable and accrued expenses | $— | $5 |
| Repurchases of treasury stock in accrued expenses | $105 | $— |
The following table provides a reconciliation of the ending cash, cash equivalents and restricted cash as of each of the periods shown above:
| SEPTEMBER 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash and cash equivalents | $259,464 | $693,472 |
| Restricted cash | 1,449 | 1,449 |
| Total cash, cash equivalents and restricted cash | $260,913 | $694,921 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.